Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 8NIH 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma, Ewing 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 331Magnetic Resonance Spectroscopy 238Biopsy 197Nivolumab 59Cyclophosphamide 52X-Rays 49Radiation 47Paclitaxel 47Carboplatin 47Cisplatin 46pembrolizumab 45Taxes 45Immunoglobulin G 45Disulfides 45Platinum 421,2-diaminocyclohexaneplatinum II citrate 42Radiotherapy 38Doxorubicin 36Ipilimumab 33Gemcitabine 32CTLA-4 Antigen 32atezolizumab 31olaparib 28fludarabine 27Vincristine 26venetoclax 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × etoposide phosphate × 90 days × Clear all
NCT02306161 2026-06-03

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
312 enrolled 14 charts
Sarcoma

Sarcoma, Ewing

NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT03983824 2026-05-13

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡